Who Owns Vistagen Therapeutics Stock?
NASDAQ: VTGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 31.05%
- Held by insiders
- 0.37%
- Institutional holders
- 58
- Institutions 31.1%
- Insiders 0.4%
- Public and other 68.6%
Who owns Vistagen Therapeutics stock?
Institutional investors own about 31.1% of Vistagen Therapeutics's shares, spread across 58 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 0.37% of VTGN.
The largest institutional holders are Commodore Capital Lp (6.28%), Vanguard Capital Management LLC (3.55%) and Two Sigma Investments, LP (1.91%). Together, the top 10 institutions control 20.5% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their VTGN positions and 1 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of VTGN
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Commodore Capital Lp | 2.79M | 6.28% | +100.0% |
| Vanguard Capital Management LLC | 1.57M | 3.55% | 0.0% |
| Two Sigma Investments, LP | 847.99K | 1.91% | +80.6% |
| Acadian Asset Management. LLC | 794.58K | 1.79% | +34.8% |
| Renaissance Technologies, LLC | 730.50K | 1.65% | +150.8% |
| Stempoint Capital LP | 616.75K | 1.39% | 0.0% |
| Ikarian Capital, LLC | 519.08K | 1.17% | 0.0% |
| AdvisorShares Investments, LLC | 438.64K | 0.99% | +58.3% |
| Luminus Management, LLC | 403.12K | 0.91% | +1.8% |
| Geode Capital Management, LLC | 365.00K | 0.82% | -19.5% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of VTGN
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.16M | 2.61% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 542.68K | 1.22% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 413.75K | 0.93% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 189.56K | 0.43% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 48.90K | 0.11% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 46.96K | 0.11% |
| Blackstone Alternative Investment Fd.s-Blackstone Alternative Multi-St | 4.95K | 0.01% |
| Guggenheim Active Allocation Fund | 38 | 0.00% |
Frequently asked questions
Who is the largest shareholder of Vistagen Therapeutics?
Commodore Capital Lp is the largest institutional shareholder of VTGN, owning 6.28% of shares outstanding (2.79M shares) as of its latest 13F filing.
What percentage of Vistagen Therapeutics is owned by institutions?
Institutions own about 31.1% of VTGN shares and 31.2% of the public float.
How much of Vistagen Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.37% of VTGN shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.